Pathway Targets to Explore in the Treatment of Small Cell and Large Cell Lung Cancers

IntroductionWith low 5-year survival rates and little progress in therapy, improvements in therapeutic strategies for the treatment of small cell lung cancer (SCLC) and large cell lung cancer (LCC) are warranted. We hypothesized that different SCLC and LCC microarray data sets will share commonly perturbed pathways leading to the identification of new targets for therapeutic development.MethodsPer gene mean expression fold change ratios were calculated from four publicly available microarray data sets consisting of a total of 113 profiled samples. This was followed by mapping of differentially expressed genes into functionally annotated biologic pathways using Ingenuity pathway analysis software. Common pathways containing genes whose expression levels differed between phenotypic classes defined by histology and gender were determined.ResultsSeveral significant common pathways overlapping these data sets were identified in silico. One of which, the Wnt/β-catenin signaling pathway, is targeted by agents such as vorinostat and dasatinib, which are currently under exploration in SCLC trials. The remaining pathways are targeted by several drugs developed or under development in cancer therapeutics.ConclusionThis in silico pathway exploration in SCLC and LCC holds promise. Additional expression profiling of SCLC and LCC cases would likely add to the knowledge base. Further investigation into identified targets is warranted.